Genmab vs Zoetis
Genmab (GMAB), health care, and Zoetis (ZTS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Zoetis is worth $33.9B on the stock market and Genmab $32B: Zoetis is valued at 6% more. Genmab trades at 44.0 times earnings and Zoetis at 14.3. Over the past year Genmab's share price has moved +70.1% and Zoetis's -28.6%.
Key facts
- Genmab market value
- $32B
- Zoetis market value
- $33.9B
- Genmab P/E
- 44.0
- Zoetis P/E
- 14.3
- Genmab revenue
- $3.7BFY to 2025-12-31
- Zoetis revenue
- $9.5BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Genmab | Zoetis |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $32Blower | $33.9Bhigher |
| Revenue | $3.7Blower | $9.5Bhigher |
| Earnings | $963Mlower | $2.7Bhigher |
| Employees | 3,244lower | 14,500higher |
| Total assets | $12.9Blower | $15.5Bhigher |
| Valuation | ||
| P/E | 44.0higher | 14.3lower |
| P/S | 8.6higher | 3.6lower |
| P/B | — | 10.3 |
| Dividend yield | — | 2.48% |
| Profitability | ||
| Operating margin | 28.6% | — |
| Balance sheet | ||
| Net assets | $5.8Bhigher | $3.3Blower |
| Total liabilities | $7Blower | $12.1Bhigher |
| Total debt | $5.3Blower | $9Bhigher |
| Cash on hand | $1.7Blower | $2.3Bhigher |
| Price change | ||
| Today | +0.76%higher | -1.08%lower |
| 1 year | +70.1%higher | -28.6%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Percentages are each holding's share of that investor's reported portfolio (under "Both": Genmab / Zoetis). Who owns GMAB · Who owns ZTS
More on Genmab
Further comparisons
Genmab against its closest peers
Zoetis against its closest peers
Learn
Questions and answers
Which is bigger, Genmab or Zoetis?
By market value, Zoetis is the larger: $33.9B against $32B for Genmab. By revenue in its latest fiscal year, Zoetis is the larger: $9.5B against $3.7B for Genmab.
Which has the higher P/E ratio?
Genmab: 44.0, against 14.3 for Zoetis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has more debt?
Zoetis: $9B, against $5.3B for Genmab. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Genmab and Zoetis?
In their latest 13F filings, Louis Bacon holds both.
Cite this page
Funkfolio, “Genmab vs Zoetis”, data as of 18 November 2026. https://funkfolio.com/compare/gmab-vs-zts
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.